# K121501: Arrow Jugular Axillo-Subclavian Central Catheter (Jacc)

- Pathway: 510(k) (Traditional)
- Applicant: Arrow International (Subsidiary of Teleflex Inc.)
- Decided: Nov 29, 2012 after 192 days
- Product code: LJS (Catheter, Intravascular, Therapeutic, Long-Term Greater Than 30 Days)
- Device class: 2
- Regulation: 21 CFR 880.5970
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 10 generations back to K001901 (2000). 33 ancestors in all.
4 later devices descend from it; 1 cites it directly.
7 of 38 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K112896: Arrw Evolution, Arrow International (Subsidiary of Teleflex Inc.) (2012) Summary page 1.
- K071538: Arrow, Arrowg+Ard and Arrowg+Ard Blue Plus Pressure Injectable Central Venous Catheter, Arrow International, Inc. (2007) Summary page 1.

## Most influential descendants
- K132133: CG+ Arrow Jacc Powered by Arrow VPS Stylet (2013), 3 descendants of its own
- K153423: CG+ Arrow JACC powered by Arrow VPS Stylet, CG+ Arrow JACC (2016), 1 descendant of its own
- K161765: CG+ Arrow JACC (2016), 0 descendants of its own
- K150109: Arrow Pressure Injectable Jugular Axillo-subclavian Central Catheter (JACC) with Sustain Technology (2015), 0 descendants of its own

## Indications for use
The Arrow Pressure Injectable Jugular Axillo-subclavian Central Catheter (JACC) with Chlorag~ard® Antimicrobial and Antithrombogenic Technology is indicated for short-term or long-term access to the central venous system for intravenous therapy, blood sampling, infusion, pressure injection of contrast media, and allows for central venous pressure monitoring. The maximum pressure of pressure injector equipment used with the Arrow Pressure Injectable JACC may not exceed 300 psi. The maximum pressure injection flow rate for the specific lumen being used for pressure injection is printed on the extension line hub. Chlorag~ard Technology treatment on the external surface of the catheter body as well as the entire fluid pathway of the catheter has been shown to be effective in reducing microbial colonization on catheter surfaces. Antimicrobial effectiveness was evaluated using in vitro and in vivo test methods and no correlation between these testing methods and clinical outcome has currently been ascertained. It is not intended to be used for the treatment of existing infections.

Source page: https://510kreport.com/device/K121501
Methodology: https://510kreport.com/methodology